image
Technology - Software - Application - NASDAQ - US
$ 39.615
-2.9 %
$ 6.27 B
Market Cap
-112.09
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VERX stock under the worst case scenario is HIDDEN Compared to the current market price of 39.6 USD, Vertex, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VERX stock under the base case scenario is HIDDEN Compared to the current market price of 39.6 USD, Vertex, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VERX stock under the best case scenario is HIDDEN Compared to the current market price of 39.6 USD, Vertex, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VERX

image
$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
667 M REVENUE
16.49%
-2.23 M OPERATING INCOME
69.99%
-52.7 M NET INCOME
-302.73%
165 M OPERATING CASH FLOW
121.74%
-158 M INVESTING CASH FLOW
-139.00%
231 M FINANCING CASH FLOW
973.26%
178 M REVENUE
4.71%
-13.1 M OPERATING INCOME
-267.65%
-67.8 M NET INCOME
-938.90%
41.1 M OPERATING CASH FLOW
-7.05%
-24.9 M INVESTING CASH FLOW
70.87%
6.25 M FINANCING CASH FLOW
139.13%
Balance Sheet Vertex, Inc.
image
Current Assets 536 M
Cash & Short-Term Investments 305 M
Receivables 164 M
Other Current Assets 66.7 M
Non-Current Assets 630 M
Long-Term Investments 0
PP&E 190 M
Other Non-Current Assets 441 M
26.16 %14.09 %5.72 %16.24 %37.79 %Total Assets$1.2b
Current Liabilities 537 M
Accounts Payable 36.2 M
Short-Term Debt 8.14 M
Other Current Liabilities 493 M
Non-Current Liabilities 450 M
Long-Term Debt 25.2 M
Other Non-Current Liabilities 425 M
3.67 %49.93 %43.03 %Total Liabilities$987.4m
EFFICIENCY
Earnings Waterfall Vertex, Inc.
image
Revenue 667 M
Cost Of Revenue 241 M
Gross Profit 426 M
Operating Expenses 428 M
Operating Income -2.23 M
Other Expenses 50.5 M
Net Income -52.7 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)667m(241m)426m(428m)(2m)(51m)(53m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
63.91% GROSS MARGIN
63.91%
-0.33% OPERATING MARGIN
-0.33%
-7.91% NET MARGIN
-7.91%
-29.40% ROE
-29.40%
-4.52% ROA
-4.52%
9.65% ROIC
9.65%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vertex, Inc.
image
100m100m90m90m80m80m70m70m60m60m50m50m40m40m30m30m20m20m10m10m0020192019202020202021202120222022202320232024202420252025
Net Income -52.7 M
Depreciation & Amortization 82.7 M
Capital Expenditures -65.8 M
Stock-Based Compensation 47.4 M
Change in Working Capital 0
Others 36.3 M
Free Cash Flow 99.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vertex, Inc.
image
Wall Street analysts predict an average 1-year price target for VERX of $50.2 , with forecasts ranging from a low of $37 to a high of $62 .
VERX Lowest Price Target Wall Street Target
37 USD -6.60%
VERX Average Price Target Wall Street Target
50.2 USD 26.72%
VERX Highest Price Target Wall Street Target
62 USD 56.51%
Price
Max Price Target
Min Price Target
Average Price Target
656560605555505045454040353530302525Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Vertex, Inc.
image
Sold
0-3 MONTHS
1.56 M USD 1
3-6 MONTHS
214 M USD 8
6-9 MONTHS
81.4 M USD 8
9-12 MONTHS
106 M USD 1
Bought
299 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector. barrons.com - 1 week ago
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely Vertex Pharmaceuticals Inc VRTX is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 12 months. benzinga.com - 1 week ago
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award “for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives.” Negulescu shares the award with Michae. businesswire.com - 3 weeks ago
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? Vertex Pharmaceuticals (VRTX -1.39%) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding into other promising billion-dollar opportunities. fool.com - 3 weeks ago
Final Trades: Vertex, Robinhood, Palo Alto and Crowdstrike The Investment Committee give you their top stocks to watch in this volatile markets. youtube.com - 3 weeks ago
Vertex Expands Chief Strategy Office to Advance E-Invoicing and Global Compliance Initiatives Leading industry experts join the Vertex Chief Strategy Office to shape product innovation and strengthen global compliance strategies for customers Leading industry experts join the Vertex Chief Strategy Office to shape product innovation and strengthen global compliance strategies for customers globenewswire.com - 3 weeks ago
Elasticsearch Now Available as a Native Grounding Engine on Google Cloud's Vertex AI Platform SAN FRANCISCO--(BUSINESS WIRE)--Elastic (NYSE: ESTC), the Search AI Company, announced that the Elasticsearch vector database is now a natively supported information retrieval engine for Google Cloud's Vertex AI platform. “By integrating Elasticsearch as a native grounding engine in Google Cloud's Vertex AI platform, our joint customers can seamlessly build RAG applications in a single workflow,” said Shay Banon, founder and chief technology officer at Elastic. “This solution enables faster dep. businesswire.com - 3 weeks ago
Is Vertex Pharmaceuticals Stock a Buy? Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (VRTX 0.75%). Compared to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date. fool.com - 3 weeks ago
Vertex to Announce First Quarter 2025 Financial Results on May 5th BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2025 Earnings Call.” The conference call will be webcast live and a link to the webcast can be a. businesswire.com - 3 weeks ago
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers' Vertex Pharmaceuticals Inc. VRTX is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx. benzinga.com - 3 weeks ago
Vertex Announces Program Updates for Type 1 Diabetes Portfolio BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunopro. businesswire.com - 1 month ago
Final Trades: Vertex Pharma, Netflix and the IYF The Investment Committee give you their stop stocks to watch for the second half. youtube.com - 1 month ago
8. Profile Summary

Vertex, Inc. VERX

image
COUNTRY US
INDUSTRY Software - Application
MARKET CAP $ 6.27 B
Dividend Yield 0.00%
Description Vertex, Inc. provides tax technology solutions for corporations in retail, communication, leasing, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Contact 2301 Renaissance Boulevard, King of Prussia, PA, 19406 https://www.vertexinc.com
IPO Date July 29, 2020
Employees 1900
Officers Mr. David DeStefano Chief Executive Officer, President & Chairman of the Board Ms. Amanda Westphal Radcliffe Co-Owner & Independent Director Mr. Bryan T. R. Rowland Senior Vice President, General Counsel & Secretary Mr. Ben Askin Chief Information Officer Mr. Salvatore Visca Chief Technology Officer Ms. Stefanie Westphal-Lucas Thompson Co-Owner & Independent Director Mr. Steven Hinckley Chief Operating Officer Mr. Ray Westphal Founder Mr. John R. Schwab Chief Financial Officer Mr. Ryan J. Leib CPA Chief Accounting Officer